Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3663 - Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections


10 Oct 2016


Poster display


Florentia Fostira


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


F. Fostira1, E. Fountzila2, A. Vagena3, P. Apostolou1, I. Konstanta1, C. Papadimitriou2, E. Razis2, C. Christodoulou2, E. Timotheadou2, V. Mollaki1, M. Papamentzelopoulou1, I.S. Vlachos1, D. Yannoukakos1, I. Konstantopoulou1

Author affiliations

  • 1 Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research ‘Demokritos’, 15310 - Athens/GR
  • 2 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 3 Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research ‘Demokritos’, Athens/GR


Abstract 3663


BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk for breast and ovarian cancer diagnosis. BRCA-related tumors display characteristic pathological features, with the BRCA1-associated being predominantly triple-negative. On the contrary, BRCA2-associated tumors are more commonly found to be estrogen/progesterone receptor (ER/PgR)-positive. The incidence of BRCA1 and BRCA2 deleterious mutations in HER2-positive breast cancers, as well as the incidence of BRCA2 deleterious mutations in triple-negative breast cancer cases has not been investigated in depth. Our aim was to explore the clinicopathological characteristics of breast cancers in BRCA mutation carriers in a Greek population.


Patients diagnosed with breast cancer between 1999 and 2016 were tested for BRCA1 and BRCA2 mutations, either by Sanger sequencing or by next generation sequencing using the Trusight Cancer 94-gene panel. A retrospective review of the medical records was conducted to retrieve patient demographics and tumor histopathological characteristics.


Out of 2096 high-risk breast cancer families tested, we identified 303 BRCA1 and 88 BRCA2 carriers (18.7%). Mean age of breast cancer diagnosis for BRCA1 and BRCA2 carriers was 40.0 years (range 19-74) and 42.8 years (range 25-71), respectively. Information on clinicopathological characteristics (including ER/PgR and HER2 status) was available for 282 (72%) of the 391 mutation carrier patients. Tumor histological subtypes in BRCA1 carriers were predominantly ductal (79%) and medullary (10%), while in BRCA2 carriers these were more frequently ductal (74%) and lobular (15%). Interestingly, 20% of the BRCA2 tumors were triple-negative, in contrast to the expected, significantly higher proportion (75%) observed in BRCA1 carriers (chi-square, p 


These data confirm established observations in the pathology of BRCA-related tumors, but provide further insight on the association of rare histological and immunohistochemical entities with loss-of-function mutations in these genes, which can be clinically important.

Clinical trial identification


Legal entity responsible for the study

Hellenic Cooperative Oncology Group, INRASTES-National Centre for Scientific Research "Demokritos"


Hellenic Cooperative Oncology Group, INRASTES-National Centre for Scientific Research "Demokritos"


F. Fostira: Advisory Board - Astra Zeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings